These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20716141)

  • 21. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G; Perico N; Macia M; Ruggenenti P
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.
    Abuissa H; O'Keefe J
    Diabetes Obes Metab; 2008 Dec; 10(12):1157-66. PubMed ID: 18494810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal protection in diabetes.
    Hunter JD; Ravert PK; Lassetter JH; Williams M
    Adv NPs PAs; 2011 Jan; 2(1):25-9; quiz 30. PubMed ID: 21329229
    [No Abstract]   [Full Text] [Related]  

  • 24. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Barnas U; Mayer G
    Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
    Parving HH
    Diabetologia; 1998 Jul; 41(7):745-59. PubMed ID: 9686914
    [No Abstract]   [Full Text] [Related]  

  • 27. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention.
    Vijayaraghavan K; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):137-56. PubMed ID: 21257105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual blockade of the renin-angiotensin system in chronic renal disease: to do or not to do.
    Nakao N; Seno H; Kasuga H; Toriyama T; Kawahara H
    Clin Exp Nephrol; 2004 Sep; 8(3):183-7. PubMed ID: 15480894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lights and shadows on single and dual RAAS blockade].
    Cavalli A; Del Vecchio L; Locatelli F
    G Ital Nefrol; 2010; 27(5):477-89. PubMed ID: 20922679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination treatment and renal function in patients with chronic kidney disease.
    Renke M; Rutkowski P; Tylicki L; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2010 Jun; 11(2):146-7. PubMed ID: 20223790
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN
    Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Normoalbuminuria at all costs?].
    Maggio M
    G Ital Nefrol; 2011; 28(4):354. PubMed ID: 21809300
    [No Abstract]   [Full Text] [Related]  

  • 35. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
    Pisoni R; Faraone R; Ruggenent P; Remuzzi G
    J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.